The aim of this review is to analyse critically the recent literature on the clinical
pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients …

The calcineurin inhibitors ciclosporin (cyclosporine) and tacrolimus are immunosuppressant
drugs used for the prevention of organ rejection following transplantation. Both agents are …

In 2007, a consortium of European experts on tacrolimus (TAC) met to discuss the most
recent advances in the drug/dose optimization of TAC taking into account specific clinical …

ABSTRACT Introduction: Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy
after solid organ transplantation and will probably remain so. Excluding belatacept, no new …

Background The deleterious side effects of calcineurin inhibitors have impaired long-term
survival after renal allograft. New immunotherapy regimens that minimize or even eliminate …

Previously, we reported that, at 3 months after renal transplantation, individuals with
CYP3AP1 genotype CYP3AP1* 1 (linked to CYP3A5* 1 and strongly associated with …

The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …

Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the
concentration–effect relationship for Tac is poorly defined. This study investigated whether …

Previously, we demonstrated that the dose-normalized tacrolimus blood concentration after
renal transplantation was associated with a single nucleotide polymorphism (SNP) in the …

Background Early after renal transplantation, it is often challenging to achieve and maintain
tacrolimus concentrations within the target range. Computerized dose individualization …